← Back to patent-cliff list
AHB-137
Tier C — Watch / tradeAHB-137
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：Not applicable
Indications (approved)：Chronic hepatitis B
Regional status
US
Phase II
2026-09-01
EU
Phase II
2026-09-01
China
Phase III
2025-08-12
Japan
Phase II
2026-03-06
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AHB-137?
Approved indications include: Chronic hepatitis B.
When does the AHB-137 patent expire?
No public expiry year is available for AHB-137 yet; this page updates once verified.
How do I get a quote for AHB-137 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30